ClinicalTrials.gg
RecruitingNCT07119528Updated Nov 28, 2025

Application-Based Integrated Care in Patients After Pulse Field Ablation

An interventional study of AF application enhancing AF education and AF application without enhancing AF education and drug adhrence in Atrial Fibrillation Patients Treated With the FARAPULSE™ PFA System, sponsored by Yonsei University. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Yonsei University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Atrial Fibrillation by Yonsei University — 25 open to participants now, 26 under way, none of them phase 3. Atrial Fibrillation · Yonsei University.

Planned enrollment
10th of 42
500 · median 259
Started
2025
with 9 others
No phase
35 of 52
19 open now
Primary completion
2029-12
later than 20 of 25 live
Registered
43rd of 52
by date

Among the 52 studies in Atrial Fibrillation by Yonsei University, this one is the 10th largest by planned enrollment of the 42 interventional ones that give a count, is one of 10 that started in 2025, is one of 35 with no phase, reaches primary completion later than 20 of the 25 other live ones, and was the 43rd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

25 of the 52 studies in Atrial Fibrillation by Yonsei University are open now, in 1 country. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Atrial Fibrillation by Yonsei University, or all of them as a file.
02

Study summary

"Atrial fibrillation (AF) is known as the most common sustained arrhythmia observed in clinical situation. Pulse Field Ablation (PFA) is a recently introduced, effective atrial fibrillation (AF) ablation modality. PFA is safe for treating patients with AF. The "MANIFEST-17K" international study showed important safety outcomes in 17,642 AF patients undergoing post-approval PFA, including no significant risk of esophageal damage, with PFA. PFA provides an appealing alternative to cryoablation and radiofrequency ablation, which often cause damage to non-targeted tissues, particularly the esophagus and phrenic nerve.

An integrated care approach including risk factor management might be of benefit to the clinical outcomes of patients with AF. A mobile application-based integrated care approach is also relatively new and can reduce the burden of physicians and nurses. Recent studies showed that an integrated care approach to holistic AF care can improve the outcome of population-based studies. However, the effect of the mobile application-based integrated care approach has not been evaluated in ablation patients.

Dementia, a decline in memory and other cognitive functions leading to disability in daily function is a common and feared geriatric condition. Although catheter ablation is one of the main treatments for AF, whether it can improve cognitive function in patients with AF remains unclear. Multiple observational trials have shown that catheter ablation is also associated with a lower risk of cognitive decline, dementia, and improved cognitive testing that can be explained through a variety of pathways.

FARAPULSE™ PFA is becoming a widely used ablation technique in AF patients, and knowing the effect of an application-based integrated care approach after AF PFA ablation, and the change in cognitive function is novel. The hypothesis of the study is that AF freedom will be improved by using an application-based integrated care approach in AF patients after the FARAPULSE™ PFA. Another hypothesis is that because of the short procedure time of PFA, the cognitive function will be improved after PFA, and further improved using an application-based integrated care approach.

Read the detailed description

This is a prospective, randomized, multicenter study including about 10 hospitals in South Korea. Among subjects treated with the FARAPULSE™ PFA system, those signing the informed consent form will be included in the study. Patients will be randomly assigned in a 1:1 ratio, with the use of a Web-based randomization system, to receive either Application-based integrated care (AF-App group, n=250) or locally available care (no-AF-App group, n=250). They will be followed by 3 Months, 6 Months, and 12 Months. The primary endpoint includes AF freedom (the "ablation and drug-free").

The app will include content related to anticoagulation therapy, such as: medication reminders or intake confirmation for anticoagulants, the importance of anticoagulation therapy in stroke prevention, the role of antiarrhythmic and rate-control medications in symptom management, the necessity of controlling risk factors such as hypertension, diabetes, and hyperlipidemia, and quality of life and cognitive function assessments through questionnaires.

Follow-up assessments will be conducted upto 12 months after enrollment. The anticipated enrollment period is 2 years, with a follow-up duration of one year.

Participants will have voluntary access to educational materials in the app. Medication adherence will be encouraged through reminder alarms, while other educational components will not have specific evaluation methods. The study investigator is responsible for developing the medication adherence education app. The app's content is currently being finalized, and development will be completed using research funding after study approval.

Randomization will be conducted using an Excel macro function, assigning participants in a 1:1 ratio. The randomization process will be uploaded to iCReaT, an electronic case report form (eCRF) system, allowing verification at the time of participant registration.

Primary Outcome: AF freedom at 12 months post-index procedure. (the "ablation and drug-free"). AF Freedom defined as: Freedom from recurrence of individual types of AF, or new AFLs or Ats between 3 month and 12-Month follow-up requiring additional ablation or AADs.

Secondary Outcomes: AF burden: average AF amount per day measured using 1-, 3- or 7-day Holter monitoring at baseline (before ablation), 6, 12 months after PFA.

03

Conditions studied

  • Atrial Fibrillation Patients Treated With the FARAPULSE™ PFA System

Browse trials for

Keywords

  • Atrial fibrillation
  • Pulse field ablation
  • Integrated care
  • Application
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. patients who were treated with the FARAPULSE™ PFA for AF as a de novo procedure
  2. Subjects who are willing and capable of providing
  3. Subjects who are willing and capable of participating in App-base integrated care Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to state and national law

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a current interatrial baffle or patch
  2. Subjects with a known or suspected atrial myxoma
  3. Subjects with myocardial infarction within 14 days prior to enrollment
  4. Subjects with a recent (within 30 days prior to enrollment) Cerebral Vascular Accident (CVA)
  5. Subjects who do not tolerate anticoagulation therapy
  6. Subjects with an active systemic infection *
  7. Subjects with a presence of atrial known thrombus *
  8. Subjects with a known inability to obtain vascular access
  9. Subjects who are pregnant or planning to be pregnant
  10. Subjects with atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible / non-cardiac causes
  11. Subjects with any prosthetic heart valve, ring, or repair including balloon aortic valvuloplasty
  12. Subjects with a to an invasive electrophysiology procedure where insertion or manipulation of a catheter in the cardiac chambers is deemed unsafe per physician's medical judgment, such as, but not limited to, a recent previous cardiac surgery (e.g., ventriculotomy or atriotomy, CABG, PTCA/PCI/coronary stent procedure/unstable angina) and/or in patients with congenital heart disease where the underlying abnormality increases the risk of the ablation (e.g., severe rotational anomalies of the heart or great vessels)
  13. Subjects with a of ≤ 1 year per investigator's opinion
  14. Subjects who are currently enrolled in another study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance must be brought to the attention of the sponsor to determine eligibility.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    App education group

    Other: AF application enhancing AF education

  • Experimental
    No-App education group

    Other: AF application without enhancing AF education and drug adhrence

Interventions

  • OtherAF application enhancing AF education

    This group will use AF-application. The app will include content related to anticoagulation therapy, such as: medication reminders or intake confirmation for anticoagulants, the importance of anticoagulation therapy in stroke prevention, the role of antiarrhythmic and rate-control medications in symptom management, the necessity of controlling risk factors such as hypertension, diabetes, and hyperlipidemia, and quality of life and cognitive function assessments through questionnaires.

  • OtherAF application without enhancing AF education and drug adhrence

    This group will use AF-application. However, this application will not contain materials enhancing AF education and adherence.

06

What researchers measure

Primary outcomes

  1. AF freedom at 12 months post-index procedure.

    Freedom from recurrence of individual types of AF, or new AFLs or Ats between 3 month and 12-Month follow-up requiring additional ablation or AADs

    Time frame: average AF amount per day measured using 1-, 3- or 7-day Holter monitoring at baseline (before ablation), 6, 12 months after PFA.

Secondary outcomes

  1. Atrial fibrillation (AF) burden

    Atrial burden refers to the proportion of time a patient experiences atrial fibrillation (AF) during a defined observation period, often expressed as a percentage. It's a crucial quantitative measure that helps in assessing stroke risk, the efficacy of antiarrhythmic treatments, and the need for oral anticoagulation. AF burden is measured using Holter monitoring (24 to 72 hours or sometimes upto 7 days) at baseline (before ablation), 6, and 12 months after PFA.

    Time frame: upto 12 month follow-up

  2. time to stroke (ischemic and hemorrhagic)

    Secondary end points assessed time to stroke (ischemic and hemorrhagic), measured as the time from randomization to the first occurrence of either of these events.

    Time frame: upto 12 month follow-up

  3. time to transient ischemic attack (TIA)

    Secondary end points assessed time to transient ischemic attack (TIA), measured as the time from randomization to the first occurrence of either of these events.

    Time frame: upto 12 month follow-up

  4. time to systemic embolism

    Secondary end points assessed time to systemic embolism, measured as the time from randomization to the first occurrence of either of these events.

    Time frame: upto 12 month follow-up

  5. time to major bleeding

    Secondary end points assessed time to major bleeding, measured as the time from randomization to the first occurrence of either of these events. Major bleeding was defined according to the criteria of International Society on Thrombosis and Haemostasis (ISTH) as clinically overt bleeding which was fatal or associated with any of the following: (a) a fall in hemoglobin level of 2 g/dL or more or documented transfusion of at least 2 units of packed red blood cells, (b) involvement of a critical anatomical site (intracranial, spinal, ocular, pericardial, articular, intramuscular with compartment syndrome, retroperitoneal).

    Time frame: upto 12 month follow-up

  6. time to clinically relevant non-major bleeding

    Secondary end points assessed time to clinically relevant non-major bleeding, measured as the time from randomization to the first occurrence of either of these events. Clinically relevant non-major bleeding define a bleeding event that is neither a major bleed as defined by the ISTH 1 nor a non-clinically consequential minor bleeding event.

    Time frame: upto 12 month follow-up

  7. time to hospitalization events

    Secondary end points assessed time to hospitalization events, measured as the time from randomization to the first occurrence of either of these events.

    Time frame: upto 12 month follow-up

07

Study locations

1 of 1 sites recruiting
  • Division of Cardiology Severance Cardiovascular Hospital, Yonsei University College of Medicine
    Seoul, 03722, South Korea
    Recruiting
    • Boyoung Joung, M.D., Ph.D. · ContactCBY690@yuhs.ac · +82-2228-8447
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2029, 53 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 53 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Aug 13, 2025
StartActual
Jul 21, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07119528
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Aug 13, 2025
Start date
Jul 21, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 28, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion